Notice: This company has been marked as potentially delisted and may not be actively trading. Kineta (KA) News Today Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsEarningsHeadlinesInsider TradesOwnershipShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period SHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Kineta, Inc. - KANTDecember 12, 2024 | prnewswire.comKineta and TuHURA Enter Acquisition AgreementNovember 25, 2024 | tipranks.comKineta Announces Completion of Enrollment in the Monotherapy Arm of the VISTA-101 Phase 1 Clinical Study in Advanced Solid TumorsOctober 18, 2024 | theglobeandmail.comKineta Announces KVA12123 Abstract Accepted for Poster Presentation at Society for Immunotherapy of Cancer (SITC) 2024October 4, 2024 | globenewswire.comKineta Announces the Extension of the TuHURA Biosciences Exclusivity and Right of First Offer Agreement for KVA12123, Kineta's VISTA blocking antibody Currently in Phase 1October 2, 2024 | globenewswire.comKineta, Inc Transitioning from Nasdaq to OTC MarketsSeptember 19, 2024 | globenewswire.comKineta, Inc.: Kineta Reopens Enrollment for the VISTA-101 Clinical Trial Evaluating KVA12123 in Patients with Advanced Solid Tumor CancerAugust 19, 2024 | finanznachrichten.deKineta Reopens Enrollment for the VISTA-101 Clinical Trial Evaluating KVA12123 in Patients with Advanced Solid Tumor CancerAugust 19, 2024 | globenewswire.comTuHURA Biosciences and Kintara Therapeutics Announce Kineta Inc. Reopens Enrollment for VISTA-101 Clinical Trial Evaluating KVA12123 in Patients with Advanced Solid Tumor CancerAugust 19, 2024 | prnewswire.comKineta Announces Exclusivity and Right of First Offer Agreement for its VISTA blocking antibody with TuHURA BiosciencesJuly 8, 2024 | globenewswire.comTuHURA Biosciences Enters into Exclusivity and Right of First Offer Agreement for Kineta, Inc.'s KVA12123 Novel anti-VISTA Checkpoint InhibitorJuly 8, 2024 | prnewswire.comKineta Inc KAMay 16, 2024 | morningstar.comKA Stock Earnings: Kineta Misses EPS for Q1 2024May 15, 2024 | msn.comKineta Reports First Quarter 2024 Financial Results and Provides Update on its Ongoing Phase 1/2 VISTA-101 Clinical Trial and Corporate ActivitiesMay 15, 2024 | globenewswire.comKineta (KA) Price Target Increased by 25.58% to 13.77April 18, 2024 | msn.comKineta, Inc.: Kineta Reports Initial Clinical Response Data at AACR 2024 of its Ongoing Phase 1/2 VISTA-101 Clinical TrialApril 9, 2024 | finanznachrichten.deKineta Reports Initial Clinical Response Data at AACR 2024 of its Ongoing Phase 1/2 VISTA-101 Clinical TrialApril 8, 2024 | globenewswire.comKineta, Inc.: Kineta Reports Full Year 2023 Financial Results and Provides Corporate UpdateMarch 22, 2024 | finanznachrichten.deKineta Reports Full Year 2023 Financial Results and Provides Corporate UpdateMarch 21, 2024 | globenewswire.comKVA12123 Clears Additional Cohorts in Monotherapy and in Combination Therapy Arms in the Phase 1/2 VISTA-101 Clinical Trial; Initial Clinical Response Data ReportedMarch 12, 2024 | globenewswire.comKineta CEO laid off as cutbacks leave biotech with 4 employeesMarch 1, 2024 | bizjournals.comKineta stock falls ~25.7% after co cuts workforce by 64%, including CEOFebruary 29, 2024 | msn.comKineta Announces Restructuring and Exploration of Strategic AlternativesFebruary 29, 2024 | globenewswire.comKineta to Present New Preclinical Data on its Anti-VISTA Antibody KVA12123 in Acute Myeloid Leukemia at the AACR Blood Cancer Discovery SymposiumFebruary 22, 2024 | finance.yahoo.comKineta to Present New Preclinical Data on its Anti-VISTA Antibody KVA12123 in Acute Myeloid Leukemia at the AACR Blood Cancer Discovery SymposiumFebruary 22, 2024 | globenewswire.comKineta to Present at Upcoming Investor ConferencesFebruary 14, 2024 | finance.yahoo.comKineta to Present at Upcoming Investor ConferencesFebruary 14, 2024 | globenewswire.comKineta to Participate in H.C. Wainwright Virtual @Home Fireside Chat SeriesFebruary 7, 2024 | stockhouse.comKA: Phase I/II UpdateJanuary 29, 2024 | finance.yahoo.comKineta, Inc.: Kineta Provides Update on its Ongoing Phase 1/2 VISTA-101 Clinical Trial of KVA12123 in Patients with Advanced Solid TumorsJanuary 17, 2024 | finanznachrichten.deKineta Publishes Preclinical Data Demonstrating the Potential of Anti-VISTA Antibody KVA12123 as an Immunomodulatory Therapy for CancerDecember 13, 2023 | finance.yahoo.comKineta to Present at the Life Sciences Investor Forum December 14thDecember 12, 2023 | finance.yahoo.comKineta to Host KOL Event to Review New Data from VISTA-101 Clinical Trial of KVA12123 in Patients with Advanced Solid Tumors on December 5, 2023November 28, 2023 | finance.yahoo.comKineta to Present at the 5th Annual Macrophage-Directed Therapies SummitNovember 9, 2023 | finance.yahoo.comBuy Rating for Kineta Backed by Promising Drug Trials and Solid Financial PerformanceNovember 8, 2023 | markets.businessinsider.comKA: Third Quarter Results - MSNNovember 7, 2023 | msn.comKA: Third Quarter ResultsNovember 7, 2023 | finance.yahoo.comKineta Unveils Positive New Data from VISTA-101 Clinical Trial of KVA12123 at the Society for Immunotherapy of Cancer's (SITC) 38th Annual MeetingNovember 6, 2023 | benzinga.comKineta Unveils Positive New Data from VISTA-101 Clinical Trial of KVA12123 at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual MeetingNovember 6, 2023 | finance.yahoo.comKineta Insider Purchases Yet To Pay Off Regardless Of Recent StrengthNovember 4, 2023 | finance.yahoo.comKineta, Inc.: Kineta Reports Third Quarter 2023 Financial Results and Provides Corporate UpdateNovember 4, 2023 | finanznachrichten.deKineta Presents New Preclinical Data on Lead Anti-CD27 Monoclonal Antibody at the Society for Immunotherapy of Cancer's (SITC) 38th Annual MeetingNovember 3, 2023 | benzinga.comKineta: Q3 Earnings SnapshotNovember 3, 2023 | chron.comKineta Presents New Preclinical Data on Lead Anti-CD27 Monoclonal Antibody at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual MeetingNovember 3, 2023 | finance.yahoo.comKineta Reports Third Quarter 2023 Financial Results and Provides Corporate UpdateNovember 3, 2023 | finance.yahoo.comPromising Prospects for Kineta’s VISTA-101 Trial and KVA12123 Monotherapy Drive Buy RatingOctober 18, 2023 | markets.businessinsider.comKineta Announces First Patient Dosed in Phase 1/2 VISTA-101 Clinical Trial of KVA12123 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Advanced Solid TumorsOctober 17, 2023 | finance.yahoo.comKA: Autumn ActivityOctober 12, 2023 | finance.yahoo.comKineta Announces KVA12123 and Anti-CD27 Agonist Antibody Abstracts Accepted for Poster Presentations at Society for Immunotherapy of Cancer (SITC) 2023October 12, 2023 | finance.yahoo.comTrading was temporarily halted for "KA" at 10:10 AM with a stated reason of "LULD pause."October 12, 2023 | marketbeat.com Get Kineta News Delivered to You Automatically Sign up to receive the latest news and ratings for KA and its competitors with MarketBeat's FREE daily newsletter. Email Address Trump’s Sending THIS Crypto Higher on Purpose (Ad)Discover the coin set to explode before 2025! Trump could trigger THIS crypto coin… YES, I WANT THE #1 CRYPTO NOW KA Media Mentions By Week KA Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. KA News Sentiment▼0.000.60▲Average Medical News Sentiment KA News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. KA Articles This Week▼00▲KA Articles Average Week Get Kineta News Delivered to You Automatically Sign up to receive the latest news and ratings for KA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Forte Biosciences News Today Daré Bioscience News Today Longeveron News Today Lipocine News Today Natural Alternatives International News Today LAVA Therapeutics News Today Pluri News Today Enlivex Therapeutics News Today Akari Therapeutics News Today Senti Biosciences News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:KA) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | SponsoredWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indi...Behind the Markets | SponsoredRare "crisis signal" triggers for third time in U.S. marketA rare pattern has just repeated for the third time in U.S. history. The last two times this happened, the...Stansberry Research | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredBuffett's Oil Bet + This 22% Dividend PlayWarren Buffett has been quietly amassing a massive position in oil stocks. But while Buffett's picks (Occid...Investors Alley | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAltcoin season moves fast, and those who hesitate are left behind. The window is closing.Crypto Swap Profits | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kineta, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Kineta With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
